Screener
Allogene Therapeutics ALLO Return on invested capital
Return on invested capital at other companies
Other financials
Where this comes from
Calculated from Allogene Therapeutics’s reported figures.
Based on trailing twelve months.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026. Open the filing →
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
FAQ
- What is Allogene Therapeutics's return on invested capital?
- Allogene Therapeutics (ALLO) reported return on invested capital of -51.3% in Q1 2026.
- How has Allogene Therapeutics's return on invested capital changed year-over-year?
- Allogene Therapeutics's return on invested capital increased by 12.4% year-over-year, from -58.6% to -51.3%.
- What is the long-term trend for Allogene Therapeutics's return on invested capital?
- Over 5 years (2020 to 2025), Allogene Therapeutics's return on invested capital has grown at a 8.5% compound annual growth rate (CAGR), from -37.5% to -56.5%.
- What does return on invested capital mean?
- Net operating profit after tax (operating income taxed at the effective rate) divided by average invested capital (debt plus equity minus cash). Measures the after-tax return on all capital put to work in the business, independent of capital structure.
Ask your AI about Allogene Therapeutics's return on invested capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude